Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network
Rheumatology International · 2024
DOI: 10.1007/s00296-024-05671-9 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Rheumatology International, 2024. Verfasst von Patrick-Pascal Strunz und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine II, Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Oberdürrbacher Straße 6, 97080, Wuerzburg, Germany. St…. Hauptthemen laut MEDLINE: Interleukin-17, Janus Kinase Inhibitors, Tumor Necrosis Factor Inhibitors, Axial Spondyloarthritis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Würzburg.
Abstract (Originalsprache)
In recent years Janus kinase inhibitors (JAKi) have joined tumor necrosis factor inhibitors (TNFi) and interleukin (IL)-17 inhibitors (IL-17i) as approved disease modifying anti-rheumatic drugs (DMARD) for moderate to severe forms of axial spondyloarthritis (axSpA). Drug survival in axSpA patients has not been well studied in a real-world outpatient scenario since the approval of JAKi. We aimed to analyze the three drug classes based on modes of actions (MoA) for their persistence rates among German axSpA outpatients. A retrospective analysis of the RHADAR database for axSpA patients with a new initiation of TNFi, IL-17i, or JAKi treatment between January 2015 and October 2023 was conducted. Analyses included Kaplan-Meier curves and adjusted Cox regressions for drug discontinuation. 1222 new biological DMARD (TNFi [ n = 954], IL-17i [ n = 190]) or JAKi ( n = 78) treatments were reported. The median drug survival was 31 months for TNFi, 25 for IL-17i, and 18 for JAKi. The corresponding 2-year drug survival rate was 79.6%, 72.6%, and 62.8% for TNFi, IL-17i, and JAKi, respectively. The probability for discontinuation for JAKi was significantly higher compared with TNFi (HR 1.91 [95% CI 1.22–2.99]) as well as for IL-17i compared with TNFi (HR 1.43 [95% CI 1.02–2.01]), possibly related to more frequent use of TNFis as first-line therapy. IL-17i and JAKi discontinuation probabilities were similar. Primary non-response was the reason for drug discontinuation in most cases across all MoA. TNFi treatment might persist longer than JAKi and IL-17i in German axSpA outpatients, possibly related to more severe or refractory disease in patients with JAKi-treated or IL-17i-treated axSpA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine II, Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Oberdürrbacher Straße 6, 97080, Wuerzburg, Germany. Strunz_P@ukw.de.
- Freelance Healthcare Data Scientist, Greven, Germany.
- Department of Rheumatology and Immunology, Medical School Hannover, Hannover, Germany.
- Department of Medicine II, Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Oberdürrbacher Straße 6, 97080, Wuerzburg, Germany.
- Clinic for Dermatology, Venereology and Allergology, University Hospital Wuerzburg, Wuerzburg, Germany.
- Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany.
ORCID-Profile: Patrick-Pascal Strunz, Matthias Englbrecht, Linus Maximilian Risser, Torsten Witte, Matthias Froehlich, Marc Schmalzing, Michael Gernert, Astrid Schmieder, Peter Bartz-Bazzanella, Cay von der Decken, Kirsten Karberg, Georg Gauler, Patrick Wurth, Susanna Späthling-Mestekemper, Christoph Kuhn, Wolfgang Vorbrüggen, Johannes Heck, Martin Welcker, Stefan Kleinert
Förderung
- Universitätsklinikum Würzburg
Zitieren
APA
Strunz, P. P., Englbrecht, M., Risser, L. M., Witte, T., Froehlich, M., Schmalzing, M., Gernert, M., Schmieder, A., Bartz-Bazzanella, P., von der Decken, C., Karberg, K., Gauler, G., Wurth, P., Späthling-Mestekemper, S., Kuhn, C., Vorbrüggen, W., Heck, J., Welcker, M., & Kleinert, S. (2024). Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network. Rheumatology International. https://doi.org/10.1007/s00296-024-05671-9
Vancouver
Strunz PP, Englbrecht M, Risser LM, Witte T, Froehlich M, Schmalzing M, et al. Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network. Rheumatology International. 2024. doi:10.1007/s00296-024-05671-9
BibTeX
@article{Strunz2024,
author = {Strunz, Patrick-Pascal and Englbrecht, Matthias and Risser, Linus Maximilian and Witte, Torsten and Froehlich, Matthias and Schmalzing, Marc and Gernert, Michael and Schmieder, Astrid and Bartz-Bazzanella, Peter and von der Decken, Cay and Karberg, Kirsten and Gauler, Georg and Wurth, Patrick and Späthling-Mestekemper, Susanna and Kuhn, Christoph and Vorbrüggen, Wolfgang and Heck, Johannes and Welcker, Martin and Kleinert, Stefan},
title = {Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network},
journal = {Rheumatology International},
year = {2024},
doi = {10.1007/s00296-024-05671-9}
}
EUVIMED